These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16397054)

  • 1. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity.
    Ko SH; Ueno T; Yoshimoto Y; Yoo JS; Abdel-Wahab OI; Abdel-Wahab Z; Chu E; Pruitt SK; Friedman HS; Dewhirst MW; Tyler DS
    Clin Cancer Res; 2006 Jan; 12(1):289-97. PubMed ID: 16397054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of hyperthermia in regional alkylating agent chemotherapy.
    Abdel-Wahab OI; Grubbs E; Viglianti BL; Cheng TY; Ueno T; Ko S; Rabbani Z; Curtis S; Pruitt SK; Dewhirst MW; Tyler DS
    Clin Cancer Res; 2004 Sep; 10(17):5919-29. PubMed ID: 15355925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
    Ueno T; Ko SH; Grubbs E; Yoshimoto Y; Augustine C; Abdel-Wahab Z; Cheng TY; Abdel-Wahab OI; Pruitt SK; Friedman HS; Tyler DS
    Mol Cancer Ther; 2006 Mar; 5(3):732-8. PubMed ID: 16546988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
    Ueno T; Ko SH; Grubbs E; Pruitt SK; Friedman HS; Tyler DS
    Am J Surg; 2004 Nov; 188(5):532-7. PubMed ID: 15546565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
    Wedge SR; Porteous JK; Newlands ES
    Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
    Yoshimoto Y; Augustine CK; Yoo JS; Zipfel PA; Selim MA; Pruitt SK; Friedman HS; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2007 May; 6(5):1492-500. PubMed ID: 17483437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
    Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
    J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor.
    Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
    Yamini B; Yu X; Gillespie GY; Kufe DW; Weichselbaum RR
    Cancer Res; 2004 Sep; 64(18):6381-4. PubMed ID: 15374943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
    Toshimitsu H; Yoshimoto Y; Augustine CK; Padussis JC; Yoo JS; Angelica Selim M; Pruitt SK; Friedman HS; Ali-Osman F; Tyler DS
    Ann Surg Oncol; 2010 Aug; 17(8):2247-54. PubMed ID: 20182810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
    Middleton MR; Kelly J; Goodger S; Thatcher N; Margison GP
    Cancer Chemother Pharmacol; 2000; 45(1):15-20. PubMed ID: 10647496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US.
    Santillan AA; Zager JS
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1033-7. PubMed ID: 20078252
    [No Abstract]   [Full Text] [Related]  

  • 18. Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
    Chen M; Osman I; Orlow SJ
    Mol Cancer Res; 2009 May; 7(5):703-12. PubMed ID: 19435820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated limb perfusion for malignant melanoma.
    Alexander HR; Fraker DL; Bartlett DL
    Semin Surg Oncol; 1996; 12(6):416-28. PubMed ID: 8914206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.